PPARG and inflammatory bowel disease: These shared functions support therapeutic strategies for IBD, such as synthetic exosomes delivering miR-223 or repurposing PPARγ agonists (e.g., pioglitazone) (36), which upregulate miR-223 and ameliorate inflammation in diabetic models and human cells (37).